Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

BMC Rheumatol · 2022 · PMC9513929 · PMID 36163193

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

Interestingly, there seemed to be an overall trend towards better effect of non-tofacitinib JAKi compared to tofacitinib in PsA.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.